156 related articles for article (PubMed ID: 35408660)
1. Discovery of Novel Epoxyketone Peptides as Lipase Inhibitors.
Almaliti J; Alzweiri M; Alhindy M; Al-Helo T; Daoud I; Deknash R; Naman CB; Abu-Irmaileh B; Bustanji Y; Hamad I
Molecules; 2022 Mar; 27(7):. PubMed ID: 35408660
[TBL] [Abstract][Full Text] [Related]
2. Development of a new class of proteasome inhibitors with an epoxyketone warhead: Rational hybridization of non-peptidic belactosin derivatives and peptide epoxyketones.
Kawamura S; Unno Y; Asai A; Arisawa M; Shuto S
Bioorg Med Chem; 2014 Jun; 22(12):3091-5. PubMed ID: 24814885
[TBL] [Abstract][Full Text] [Related]
3. Exploring dual electrophiles in peptide-based proteasome inhibitors: carbonyls and epoxides.
Xin BT; de Bruin G; Verdoes M; Filippov DV; van der Marel GA; Overkleeft HS
Org Biomol Chem; 2014 Aug; 12(30):5710-8. PubMed ID: 24968066
[TBL] [Abstract][Full Text] [Related]
4. Development of peptide epoxyketones as selective immunoproteasome inhibitors.
Li X; Hong D; Zhang M; Xu L; Zhou Y; Li J; Liu T
Eur J Med Chem; 2021 Oct; 221():113556. PubMed ID: 34087498
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and biological evaluation of novel tripeptidyl epoxyketone derivatives constructed from β-amino acid as proteasome inhibitors.
Zhang J; Cao J; Xu L; Zhou Y; Liu T; Li J; Hu Y
Bioorg Med Chem; 2014 Jun; 22(11):2955-65. PubMed ID: 24767818
[TBL] [Abstract][Full Text] [Related]
6. Multiplexed metagenome mining using short DNA sequence tags facilitates targeted discovery of epoxyketone proteasome inhibitors.
Owen JG; Charlop-Powers Z; Smith AG; Ternei MA; Calle PY; Reddy BV; Montiel D; Brady SF
Proc Natl Acad Sci U S A; 2015 Apr; 112(14):4221-6. PubMed ID: 25831524
[TBL] [Abstract][Full Text] [Related]
7. Chemoenzymatic Synthesis of Novel Cytotoxic Epoxyketones Using the Eponemycin Biosynthetic Enzyme EpnF.
Corless BC; Geißen R; Prescott NA; David Y; Scheinberg DA; Tan DS
ACS Chem Biol; 2023 Jun; 18(6):1360-1367. PubMed ID: 37172287
[TBL] [Abstract][Full Text] [Related]
8. Development of Potent and Highly Selective Epoxyketone-Based Plasmodium Proteasome Inhibitors.
Almaliti J; Fajtová P; Calla J; LaMonte GM; Feng M; Rocamora F; Ottilie S; Glukhov E; Boura E; Suhandynata RT; Momper JD; Gilson MK; Winzeler EA; Gerwick WH; O'Donoghue AJ
Chemistry; 2023 Apr; 29(20):e202203958. PubMed ID: 36617500
[TBL] [Abstract][Full Text] [Related]
9. Covalent docking modelling-based discovery of tripeptidyl epoxyketone proteasome inhibitors composed of aliphatic-heterocycles.
Dong XW; Zhang JK; Xu L; Che JX; Cheng G; Hu XB; Sheng L; Gao AH; Li J; Liu T; Hu YZ; Zhou YB
Eur J Med Chem; 2019 Feb; 164():602-614. PubMed ID: 30639896
[TBL] [Abstract][Full Text] [Related]
10. Macyranones: Structure, Biosynthesis, and Binding Mode of an Unprecedented Epoxyketone that Targets the 20S Proteasome.
Keller L; Plaza A; Dubiella C; Groll M; Kaiser M; Müller R
J Am Chem Soc; 2015 Jul; 137(25):8121-30. PubMed ID: 26050527
[TBL] [Abstract][Full Text] [Related]
11. Identifying the Minimal Enzymes Required for Biosynthesis of Epoxyketone Proteasome Inhibitors.
Liu J; Zhu X; Zhang W
Chembiochem; 2015 Dec; 16(18):2585-9. PubMed ID: 26477320
[TBL] [Abstract][Full Text] [Related]
12. Systematic Analyses of Substrate Preferences of 20S Proteasomes Using Peptidic Epoxyketone Inhibitors.
Huber EM; de Bruin G; Heinemeyer W; Paniagua Soriano G; Overkleeft HS; Groll M
J Am Chem Soc; 2015 Jun; 137(24):7835-42. PubMed ID: 26020686
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and biological evaluation of peptidyl epoxyketone proteasome inhibitors composed of β-amino acids.
Zhang J; Han M; Ma X; Xu L; Cao J; Zhou Y; Li J; Liu T; Hu Y
Chem Biol Drug Des; 2014 Nov; 84(5):497-504. PubMed ID: 24751157
[TBL] [Abstract][Full Text] [Related]
14. Towards subunit-specific proteasome inhibitors: synthesis and evaluation of peptide alpha',beta'-epoxyketones.
Elofsson M; Splittgerber U; Myung J; Mohan R; Crews CM
Chem Biol; 1999 Nov; 6(11):811-22. PubMed ID: 10574782
[TBL] [Abstract][Full Text] [Related]
15. Development and characterization of proteasome inhibitors.
Bo Kim K; Fonseca FN; Crews CM
Methods Enzymol; 2005; 399():585-609. PubMed ID: 16338383
[TBL] [Abstract][Full Text] [Related]
16. Genetic basis for the biosynthesis of the pharmaceutically important class of epoxyketone proteasome inhibitors.
Schorn M; Zettler J; Noel JP; Dorrestein PC; Moore BS; Kaysser L
ACS Chem Biol; 2014 Jan; 9(1):301-9. PubMed ID: 24168704
[TBL] [Abstract][Full Text] [Related]
17. Development of Macrocyclic Peptides Containing Epoxyketone with Oral Availability as Proteasome Inhibitors.
Li D; Zhang X; Ma X; Xu L; Yu J; Gao L; Hu X; Zhang J; Dong X; Li J; Liu T; Zhou Y; Hu Y
J Med Chem; 2018 Oct; 61(20):9177-9204. PubMed ID: 30265557
[TBL] [Abstract][Full Text] [Related]
18. Nature of pharmacophore influences active site specificity of proteasome inhibitors.
Screen M; Britton M; Downey SL; Verdoes M; Voges MJ; Blom AE; Geurink PP; Risseeuw MD; Florea BI; van der Linden WA; Pletnev AA; Overkleeft HS; Kisselev AF
J Biol Chem; 2010 Dec; 285(51):40125-34. PubMed ID: 20937826
[TBL] [Abstract][Full Text] [Related]
19. Discovery of novel covalent proteasome inhibitors through a combination of pharmacophore screening, covalent docking, and molecular dynamics simulations.
Li A; Sun H; Du L; Wu X; Cao J; You Q; Li Y
J Mol Model; 2014 Nov; 20(11):2515. PubMed ID: 25394401
[TBL] [Abstract][Full Text] [Related]
20. Development of Novel Epoxyketone-Based Proteasome Inhibitors as a Strategy To Overcome Cancer Resistance to Carfilzomib and Bortezomib.
Lee MJ; Bhattarai D; Yoo J; Miller Z; Park JE; Lee S; Lee W; Driscoll JJ; Kim KB
J Med Chem; 2019 May; 62(9):4444-4455. PubMed ID: 30964987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
